哮喘联盟

   摘要
   简介：随着人口老龄化和哮喘的患病率不断增加，这种疾病在老年人中变得更普遍。然而，严重哮喘的控制是非常复杂的，主要原因是65岁以上患者发生不可控哮喘的风险增加，还有部分原因是老年人群的固有特性：并发症、对过敏的低估、依从性差和使用吸入装置困难等。
   病例报告：我们报告了两例75岁以上严重持续性过敏性哮喘的女性病例，吸入高剂量糖皮质激素和长效β-2受体激动剂哮喘均不能得到控制，我们开始给予奥马珠单抗治疗。我们发现随着奥马珠单抗的治疗，患者病情恶化的次数减少、严重程度减轻，哮喘控制得到改善且全身糖皮质激素的用量减少或停用。在两个病例中，奥马珠单抗的耐受性都很好。
   结论：奥马珠单抗是一种针对患有控制不良严重过敏性哮喘老人有效且耐受良好的治疗选择。
 

（杨冬 审校）
RevMalRespir. 2015Sep4.pii:S0761-8425(15)00297-1.doi:10.1016/j.rmr.2015.07.005. [Epub ahead of print]

 

Severe uncontrolled asthma in patients over 75 years old: Treatment with omalizumab.
 

[Article in French]
Romand P1, Kelkel E2, Saint-Raymond C3, Glas N4, Caillaud D5, Devouassoux G6.
 

Abstract
INTRODUCTION:With an aging population and an increase in the prevalence of asthma, this disease is becoming more common in the elderly. Nevertheless, the management of severe asthma can be complex, due to an increased risk of uncontrolled disease in patients over 65 years old and partly to the inherent characteristics of old age: comorbidities, underestimation of the role of allergies, poor adherence, difficulties with inhalation devices, etc.
CASE REPORTS:We report two cases of women over 75 with severe persistent allergic asthma not controlled by high doses of inhaled corticosteroids and long-acting beta-2-agonists in whom treatment with omalizumab was initiated. Following treatment with omalizumab a decrease in the number and severity of exacerbations, improved asthma control and dose reduction or discontinuation of systemic corticosteroids were observed. The tolerance of omalizumab was good in both cases.
CONCLUSIONS:Omalizumab is to be considered an effective and well-tolerated therapeutic option for elderly patients with inadequately controlled severe allergic asthma.

RevMalRespir. 2015Sep4.pii:S0761-8425(15)00297-1.doi:10.1016/j.rmr.2015.07.005. [Epub ahead of print]